Dacarbazine

Breastfeeding
  • TRADE NAMES: Dacatic; Deticene; Detimedac; DTIC; DTIC-Dome (Bayer)
  • INDICATIONS: Malignant melanoma, carcinomas
  • SYNONYM: DIC
  • CLASS: Alkylating agent, Antineoplastic
  • HALF-LIFE: 5 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aldesleukin

PREGNANCY CATEGORY: C

Our database has 54 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
NAILS
MUCOSAL
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
LOCAL
NEUROMUSCULAR/SKELETAL
RESPIRATORY
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top